ES2385032T3 - Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas - Google Patents

Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas Download PDF

Info

Publication number
ES2385032T3
ES2385032T3 ES03725536T ES03725536T ES2385032T3 ES 2385032 T3 ES2385032 T3 ES 2385032T3 ES 03725536 T ES03725536 T ES 03725536T ES 03725536 T ES03725536 T ES 03725536T ES 2385032 T3 ES2385032 T3 ES 2385032T3
Authority
ES
Spain
Prior art keywords
polypeptide
cell
vaccine according
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03725536T
Other languages
English (en)
Spanish (es)
Inventor
Jan Holgersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recopharma AB
Original Assignee
Recopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recopharma AB filed Critical Recopharma AB
Application granted granted Critical
Publication of ES2385032T3 publication Critical patent/ES2385032T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES03725536T 2002-04-22 2003-04-22 Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas Expired - Lifetime ES2385032T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37509502P 2002-04-22 2002-04-22
US375095P 2002-04-22
PCT/IB2003/002207 WO2003088995A2 (en) 2002-04-22 2003-04-22 Mucin fusion polypeptide vaccines, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
ES2385032T3 true ES2385032T3 (es) 2012-07-17

Family

ID=29251230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03725536T Expired - Lifetime ES2385032T3 (es) 2002-04-22 2003-04-22 Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas

Country Status (8)

Country Link
US (2) US8034351B2 (https=)
EP (1) EP1517700B1 (https=)
JP (1) JP2005530493A (https=)
AT (1) ATE551069T1 (https=)
AU (1) AU2003228067B2 (https=)
CA (1) CA2483473A1 (https=)
ES (1) ES2385032T3 (https=)
WO (1) WO2003088995A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1531842A4 (en) 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc REGULATION OF CELL GROWTH BY MUC1
JP2005532793A (ja) * 2002-04-22 2005-11-04 レコファーマ アーベー 微生物付着を阻害するための融合ポリペプチドおよび方法
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
JP4549666B2 (ja) * 2003-12-12 2010-09-22 タカラバイオ株式会社 抗体の製造方法
US7807636B1 (en) 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
WO2006081553A2 (en) 2005-01-28 2006-08-03 Ramot At Tel Aviv University, Ltd. ANTI-MUC1 α/ß ANTIBODIES
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
JP2009544760A (ja) * 2006-01-23 2009-12-17 レコファーマ アーベー 酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用
EP2264060B1 (en) * 2006-01-26 2014-04-23 Recopharma AB Compositions and methods for inhibiting viral adhesion
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008118487A2 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
US20090280104A1 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
AU2009251328B2 (en) * 2008-05-30 2014-10-02 Glycofi, Inc. Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose
AU2011347237A1 (en) * 2010-12-21 2013-07-11 Recopharma Ab Tear substitutes
US9156897B2 (en) * 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
CN104800838B (zh) * 2015-04-14 2018-01-09 深圳市中联生物科技开发有限公司 MUC1‑Fc多肽疫苗及其制备方法和应用
JP6441167B2 (ja) * 2015-05-15 2018-12-19 愛三工業株式会社 蒸発燃料処理装置
US11918634B2 (en) * 2017-08-10 2024-03-05 Good T Cells, Inc. Method for activating T cells for cancer treatment
MX2023011268A (es) 2021-03-24 2023-12-14 Alkermes Inc Anticuerpos upar y proteínas de fusión con estos.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4710761A (en) 1985-07-09 1987-12-01 American Telephone And Telegraph Company, At&T Bell Laboratories Window border generation in a bitmapped graphics workstation
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0406857B1 (en) * 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
AU2158995A (en) * 1994-03-15 1995-10-03 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising alpha-galactosyl epitopes
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
WO1998034957A1 (en) * 1997-02-11 1998-08-13 Immunomedics, Inc. STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
SE9701127D0 (sv) * 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes

Also Published As

Publication number Publication date
EP1517700B1 (en) 2012-03-28
CA2483473A1 (en) 2003-10-30
WO2003088995A3 (en) 2004-06-03
WO2003088995A2 (en) 2003-10-30
JP2005530493A (ja) 2005-10-13
US20040002585A1 (en) 2004-01-01
US20120034220A1 (en) 2012-02-09
US8034351B2 (en) 2011-10-11
AU2003228067B2 (en) 2008-05-29
EP1517700A2 (en) 2005-03-30
ATE551069T1 (de) 2012-04-15
AU2003228067A1 (en) 2003-11-03

Similar Documents

Publication Publication Date Title
ES2385032T3 (es) Vacunas de polipéptido de fusión de mucina, composiciones y métodos de uso de las mismas
Wu et al. Protective epitope discovery and design of MUC1-based vaccine for effective tumor protections in immunotolerant mice
Wu et al. Synthesis and immunological evaluation of disaccharide bearing MUC-1 glycopeptide conjugates with virus-like particles
KR102581747B1 (ko) 표적 세포 표면 편집을 위한 접합체
Yin et al. Recent development in carbohydrate based anticancer vaccines
Yin et al. Antitumor humoral and T cell responses by mucin-1 conjugates of bacteriophage Qβ in wild-type mice
Karmakar et al. Synthesis of a liposomal MUC1 glycopeptide-based immunotherapeutic and evaluation of the effect of L-rhamnose targeting on cellular immune responses
CN110573522B (zh) SIRPα-41BBL融合蛋白及其使用方法
AU2018256453B2 (en) Methods and compositions for treating cancer with ECM-affinity peptides linked to immunotherapeutic antibodies
JP2011502520A (ja) 疾患治療のためのマンノース結合レクチンの融合タンパク質
McDonald et al. Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates
ES2309992T3 (es) Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno.
CN104284680A (zh) 使用对受体的亲和力增加的突变型light分子用于癌症治疗的方法和组合物
JP2024069367A (ja) サイトカインに連結させたｅｃｍ親和性ペプチドを用いてがんを処置するための方法および組成物
JP2002517249A (ja) 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強
US20070003514A1 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
CN115135335A (zh) 使用用经设计锚蛋白重复蛋白(darpin)官能化的纳米粒向免疫效应细胞的体外和体内基因递送
CN115551530A (zh) 经修饰的tff2多肽
ES2366552T3 (es) Síntesis enzimática a gran escala de glicoconjugados de mucina y sus aplicaciones en inmunología.
WO2008031126A1 (en) Multi-component tumour vaccine
JP2023145622A (ja) ＣＨＯ細胞で発現されたｈｅｔ ＩＬ－１５
Hossain et al. Liposomal fc domain conjugated to a cancer vaccine enhances both humoral and cellular immunity
Li et al. Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy
AU2003232994B2 (en) Lewis Y epitope modified polypeptide, or mucin fusion polypeptide, tumor vaccines
Du et al. Diphtheria toxoid-derived T-helper epitope and α-galactosylceramide synergistically enhance the immunogenicity of glycopeptide antigen